Esperion Therapeutics (ESPR) Return on Capital Employed (2013 - 2026)

Esperion Therapeutics has reported Return on Capital Employed for 14 years, with the latest figure at 46.25% in Q1 2026.

• For the quarter ending Q1 2026, Return on Capital Employed rose 10973.0% year-over-year to 46.25%; the trailing twelve-month figure through Mar 2026 stood at 46.25% (up 10973.0% YoY), and the FY2025 full-year result was 57.93%, down 13245.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 46.25%, down from 52.8% in the prior quarter.
• The five-year high for Return on Capital Employed was 844.13% in Q3 2025, with the low at 271.36% in Q4 2023.
• Historically, Return on Capital Employed has averaged 11.01% across 5 years, with a median of 66.01% in 2022.
• Annual changes were most pronounced in 2023 — Return on Capital Employed slumped 17592 bps — and 2025, when it jumped 83430 bps.
• Esperion Therapeutics' Return on Capital Employed stood at 95.44% in 2022, then tumbled by 184 bps to 271.36% in 2023, then soared by 124 bps to 65.75% in 2024, then decreased by 20 bps to 52.8% in 2025, then fell by 12 bps to 46.25% in 2026.
• The last three Return on Capital Employed figures came in at 46.25% (Q1 2026), 52.8% (Q4 2025), and 844.13% (Q3 2025), per Business Quant data.